(Q47299474)

13 January 2018

title

Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. (English)

1 reference

13 January 2018

1 reference

1 reference

1 reference

6

Hans D Ochs

1 reference

13 January 2018

author name string

Christopher M Bearden

1

1 reference

13 January 2018

Avinash Agarwal

2

1 reference

13 January 2018

Benita K Book

3

1 reference

13 January 2018

Carlos A Vieira

4

1 reference

13 January 2018

Richard A Sidner

5

1 reference

13 January 2018

Marquerite Young

7

1 reference

13 January 2018

Mark D Pescovitz

8

1 reference

13 January 2018

language of work or name

English

0 references

publication date

1 January 2005

1 reference

13 January 2018

American Journal of Transplantation

published in

1 reference

13 January 2018

volume

5

1 reference

13 January 2018

issue

1

1 reference

13 January 2018

page(s)

50-57

1 reference

13 January 2018

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2003.00646.X

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2003.00646.X

Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2003.00646.X

Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2003.00646.X

Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2003.00646.X

Abnormal antibody responses in patients with persistent generalized lymphadenopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2003.00646.X

Acquired disorders of phagocyte function complicating medical and surgical illnesses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2003.00646.X

Infliximab improves quality of life in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2003.00646.X

Use of infliximab in pediatric patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2003.00646.X

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2003.00646.X

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2003.00646.X

Sensitization following Thymoglobulin and Atgam rejection therapy as determined with a rapid enzyme-linked immunosorbent assay. US Thymoglobulin Multi-Center Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2003.00646.X

The OKT3 Antibody Response Study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2003.00646.X

10.1111/J.1600-6143.2003.00646.X

21 January 2018

Identifiers

DOI

1 reference

13 January 2018

1 reference

13 January 2018